Source: Annual Congress 2010 - Current issues in malignant pleural diseases
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
A. Abakay, A. C. Tanrikulu, Y. Celik, M. A. Kaplan, M. Kucukoner, C. Sezgi, A. Senyigit, A. Isikdogan (Diyarbakir, Turkey). Prognostic value of treatment outcomes patients with malignant pleural mesothelioma. Eur Respir J 2010; 36: Suppl. 54, 3321

Member's Comments

No comment yet.

Related content which might interest you: Prognostic significance of pleural tumour burden in patients with malignant pleural effusions Source: Annual Congress 2010 - 100 years of thoracoscopy: still room for improvement? Year: 2010 Prognostic significance of pretreatment clinical and laboratory characteristics in patients with diffuse malignant pleural mesothelioma Source: Eur Respir J 2006; 28: Suppl. 50, 784s Year: 2006 Therapeutic outcome and prognostic factors in patients with pleural mesothelioma Source: Eur Respir J 2005; 26: Suppl. 49, 73s Year: 2005 Prognostic characteristics of malignant pleural mesothelioma Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 Pre-therapeutic staging and prognostic factors in malignant pleural mesothelioma patients Source: Annual Congress 2009 - Malignant pleural mesothelioma guidelines Year: 2009 Prognostic impact of histology and treatment modalities in malignant mesothelioma Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies Year: 2013 Prognostic factors in diffuse malignant pleural mesothelioma Source: Eur Respir J 2003; 22: Suppl. 45, 62s Year: 2003 Prognostic factors in diffuse malignant pleural mesothelioma Source: Eur Respir J 2007; 30: Suppl. 51, 755s Year: 2007 Clinical and morphological prognostic factors in patients with malignant pleura mesothelioma (MPM) Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010 Prognostic significance of serum and pleural mesothelin in malignant pleural mesothelioma (MPM) Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 Is comorbidity a good prognostic factor for malignant pleural mesothelioma? Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008 Malignant pleural mesothelioma clinical aspects and survival in 93 cases Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010 Survival time in patients with malignant pleural mesothelioma Source: Annual Congress 2007 - Rare tumours, risk factors and epidemiology in thoracic oncology Year: 2007 Prognostic factors in patients with malignant pleural effusion undergoing thoracoscopy Source: Annual Congress 2011 - From outside to inside: access to the pleura Year: 2011 The impact of multimodal treatment approaches in patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Diagnostic and therapeutic problems in surgical oncology Year: 2010 Diagnostic value and prognostic significance of pleural C-reactive protein in lung cancer with malignant pleural effusions Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology Year: 2012 Malignant pleural mesothelioma (MPM): clinical presentation, complications and survival Source: Eur Respir J 2002; 20: Suppl. 38, 272s Year: 2002 Is there any advantage of chemotherapy on survival of patients with diffuse malignant pleural mesothelioma? Source: Eur Respir J 2003; 22: Suppl. 45, 29s Year: 2003 Videothoracoscopy in diagnosis and palliative treatment of malignant pleural mesothelioma Source: Annual Congress 2008 - Biology and diagnosis of thoracic tumours Year: 2008 The presence of human mammaglobin transcripts in the pleural effusion is not predictive of survival in patients with malignant mesothelioma Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008